Drug, patient, and physician characteristics associated with off-label prescribing in primary care

Archives of Internal Medicine

Volumn 172, Issue 10, 2012, Pages 781-788

  Eguale, Tewodros ^a   Buckeridge, David L ^a   Winslade, Nancy E ^a   Benedetti, Andrea ^a   Hanley, James A ^a   Tamblyn, Robyn ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CANADA; CLINICAL ARTICLE; COMORBIDITY; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED PRACTICE; FEMALE; GENERAL PRACTITIONER; HUMAN; MALE; MEDICAL DOCUMENTATION; OFF LABEL DRUG USE; PATIENT ATTITUDE; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT INDICATION;

ADULT; AGED; ATTITUDE OF HEALTH PERSONNEL; DRUG PRESCRIPTIONS; ELECTRONIC PRESCRIBING; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; PREVALENCE; PRIMARY HEALTH CARE; QUEBEC; RISK ASSESSMENT; SAFETY MANAGEMENT; TOTAL QUALITY MANAGEMENT;

EID: 84861682205     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.340     Document Type: Article

References (43)

1. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-1026.
2. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-588. (Pubitemid 27360757)
3. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281(18):1728-1734. (Pubitemid 29226484)
4. Information for healthcare professionals: tiagabine hydrochloride (marketed as Gabitril)-seizures in patients without epilepsy. Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm126114.htm. Accessed May 24, 2011.
5. FDA drug safety communication: new risk management plan and patient medication guide for Qualaquin (quinine sulfate). Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm218202.htm. Accessed May 29, 2011.
6. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154(8):529-540.
7. Dal Pan GJ. Monitoring the safety of off-label medicine use. WHO Drug Inf. 2009; 23(1):21-22.
8. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy. 2008;28(12):1443-1452.
9. Schiff GD, Rucker TD. Computerized prescribing: building the electronic infrastructure for better medication usage. JAMA. 1998;279(13):1024-1029. (Pubitemid 28173003)
10. Holbrook A, Grootendorst P, Willison D, Goldsmith C, Sebaldt R, Keshavjee K. Can current electronic systemsmeet drug safety and effectiveness requirements? AMIA Annu Symp Proc. 2005:335-339.
11. Tamblyn R, Huang A, Kawasumi Y, et al. The development and evaluation of an integrated electronic prescribing and drug management system for primary care. J Am Med Inform Assoc. 2006;13(2):148-159. (Pubitemid 43332905)
12. Vigilance Santé home page. http://www.vigilance.ca/en/index.html. Accessed February 15, 2011.
13. Eguale T, Tamblyn R, Winslade N, Buckeridge D. Detection of adverse drug events and other treatment outcomes using an electronic prescribing system. Drug Saf. 2008;31(11):1005-1016.
14. Eguale T, Winslade N, Hanley JA, Buckeridge DL, Tamblyn R. Enhancing pharmacosurveillance with systematic collection of treatment indication in electronic prescribing: a validation study in Canada. Drug Saf. 2010;33(7):559-567.
15. Health Canada drug product database. Health Canada website. http://webprod.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp. Accessed July 7, 2009.
16. Abernethy AP, Raman G, Balk EM, et al. Systematic review: reliability of compendia methods for off-label oncology indications. Ann Intern Med. 2009;150 (5):336-343.
17. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791-1800.
18. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry. 1992;149(5):587-595.
19. Jones HE, Fitzgerald H, Johnson RE. Males and females differ in response to opioid agonist medications. Am J Addict. 2005;14(3):223-233. (Pubitemid 40981209)
20. Rijcken CA, Boelema GJ, Slooff CJ, Beuger PJ, Tanja TA, de Jong-van den Berg LT. Off-label use of antipsychotics in the community pharmacy: the sex differences. Pharmacopsychiatry. 2003;36(5):187-191. (Pubitemid 37357366)
21. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373-380. (Pubitemid 30051756)
22. Haayer F. Rational prescribing and sources of information. Soc Sci Med. 1982; 16(23):2017-2023. (Pubitemid 13223086)
23. Tamblyn R, McLeod P, Hanley JA, Girard N, Hurley J. Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care. 2003;41(8):895-908.
24. Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet. 1993;342(8872):658-661. (Pubitemid 23271508)
25. Green LA, Gorenflo DW, Wyszewianski L; Michigan Consortium for Family Practice Research. Validating an instrument for selecting interventions to change physician practice patterns: aMichigan Consortium for Family Practice research study. J Fam Pract. 2002;51(11):938-942. (Pubitemid 35291615)
26. Green LA, Wyszewianski L, Lowery JC, Kowalski CP, Krein SL. An observational study of the effectiveness of practice guideline implementation strategies examined according to physicians' cognitive styles. Implement Sci. 2007;2:41. doi:10.1186/1748-5908-2-41.
27. Carey V, Zeger SC, Diggle P. Modelling multivariate binary data with alternating logistic regressions. Biometrika. 1993;80(3):517-526. doi:10.1093/biomet /80.3.517. http://www.jstor.org/stable/2337173. Accessed January 16, 2010.
28. Ananth CV, Kantor ML. Modeling multivariate binary responses with multiple levels of nesting based on alternating logistic regressions: an application to caries aggregation. J Dent Res. 2004;83(10):776-781. (Pubitemid 41766158)
29. Preisser JS, Arcury TA, Quandt SA. Detecting patterns of occupational illness clustering with alternating logistic regressions applied to longitudinal data. Am J Epidemiol. 2003;158(5):495-501. (Pubitemid 37022848)
30. Virabhak S, Shinogle JA. Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am J Manag Care. 2005;11(spec No.):SP14-SP20.
31. Chen DT, Wynia MK, Moloney RM, Alexander GC. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf. 2009;18(11):1094-1100.
32. Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the Therapeutics and Technology Assessment subcommittee of the American Academy of Neurology. Neurology. 2010;74(8):691-696.
33. Clinch CR, Kahill A, Klatt LA, Stewart D. What is the best approach to benign paroxysmal positional vertigo in the elderly? J Fam Pract. 2010;59(5):295-297.
34. Demonaco HJ, Ali A, Hippel E. The major role of clinicians in the discovery of off-label drug therapies. Pharmacotherapy. 2006;26(3):323-332. (Pubitemid 43334671)
35. Stafford RS. Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427-1429. (Pubitemid 351482734)
36. Bazzano AT, Mangione-Smith R, Schonlau M, Suttorp MJ, Brook RH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr. 2009; 9(2):81-88.
37. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med. 2009;169 (19):1745-1747.
38. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544-548. (Pubitemid 44816941)
39. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359-1369.
40. Government of Canada supports electronic health record system that will save time and lives. Health Canada website. http://www.hc-sc.gc.ca/ahc-asc/ media/nr-cp/-2009/2009-14-eng.php. Accessed July 8, 2009.
41. Bristol N. Obama allocates funds for health-care priorities. Lancet. 2009;373(9667): 881-882.
42. Blumenthal D, Tavenner M. The "meaningful use" regulation for electronic health records. N Engl J Med. 2010;363(6):501-504.
43. Classen DC, Bates DW. Finding the meaning in meaningful use. N Engl J Med. 2011;365(9):855-858.